Levodopa for the Treatment of Parkinson's Disease
The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
A 62-year-old man presents with Parkinson's disease, and treatment with levodopa is recommended. Levodopa, a naturally occurring amino acid that is metabolized to dopamine in the brain, is considered the most effective drug available for Parkinson's disease. However, after several years of therapy, serious side effects, including motor fluctuations and dyskinesias, may occur.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ehringer, H., & Hornykiewicz, O. (1960) · Klinische Wochenschrift · doi:10.1007/bf01485901 · Cited by 1,867
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,454
Modification of Parkinsonism — Chronic Treatment with L-Dopa
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902132800701 · Cited by 1,284
Holford, N. H. G., & Sheiner, L. B. (1981) · Clinical Pharmacokinetics · doi:10.2165/00003088-198106060-00002 · Cited by 1,143
Responses of monkey dopamine neurons during learning of behavioral reactions
Ljungberg, T., Apicella, P., & Schultz, W. (1992) · Journal of Neurophysiology · doi:10.1152/jn.1992.67.1.145 · Cited by 987
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Parkinson Study Group (2002) · JAMA · doi:10.1001/jama.287.13.1653 · Cited by 711
Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling
Witjas, T., Kaphan, E., Azulay, J. P., Blin, O., Ceccaldi, M., Pouget, J., Poncet, M., & Chérif, A. A. (2002) · Neurology · doi:10.1212/wnl.59.3.408 · Cited by 642
Cited by
Direct and indirect pathways of basal ganglia: a critical reappraisal
Calabresi, P., Picconi, B., Tozzi, A., Ghiglieri, V., & Di Filippo, M. (2014) · Nature Neuroscience · doi:10.1038/nn.3743 · Cited by 828
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
Self-citationMollenhauer, B., Locascio, J. J., Schulz-Schaeffer, W., Sixel-Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 622
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics
LeWitt, P. A. (2015) · Movement Disorders · doi:10.1002/mds.26082 · Cited by 391
Self-citationMa, K., Xiong, N., Shen, Y., Han, C., Liu, L., Zhang, G., Wang, L., Guo, S., Guo, X., Xia, Y., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00001 · Cited by 379
Jin, H., Kanthasamy, A., Ghosh, A., Anantharam, V., Kalyanaraman, B., & Kanthasamy, A. G. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.007 · Cited by 361
Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease
Verschuur, C. V. M., Suwijn, S. R., Boel, J. A., Post, B., Bloem, B. R., van Hilten, J. J., van Laar, T., Tissingh, G., Munts, A. G., Deuschl, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809983 · Cited by 353
Molecular Mechanisms behind Free Radical Scavengers Function against Oxidative Stress
Ahmadinejad, F., Geir Møller, S., Hashemzadeh-Chaleshtori, M., Bidkhori, G., & Jami, M.-S. (2017) · Antioxidants · doi:10.3390/antiox6030051 · Cited by 297
Review: Deep brain stimulation in Parkinson’s disease
Groiss, S. J., Wojtecki, L., Südmeyer, M., & Schnitzler, A. (2009) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285609339382 · Cited by 280
Moreno-Betancur, M., Latouche, A., Menvielle, G., Kunst, A. E., & Rey, G. (2015) · Epidemiology · doi:10.1097/ede.0000000000000311 · Cited by 279
kappa-Opioid receptor signaling and brain reward function
Bruijnzeel, A. W. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.09.008 · Cited by 214
Tsang, K., Chi, I., Ho, S., Lou, V. W., Lee, T. M. C., & Chu, L. (2002) · Movement Disorders · doi:10.1002/mds.10249 · Cited by 69
Lee, C.-H., & Hung, S.-Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010031 · Cited by 50
Biodegradable Microspheres Loaded with an Anti-Parkinson Prodrug: An in Vivo Pharmacokinetic Study
D'Aurizio, E., Sozio, P., Cerasa, L. S., Vacca, M., Brunetti, L., Orlando, G., Chiavaroli, A., Kok, R. J., Hennink, W. E., & Di Stefano, A. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200337h · Cited by 38
Metadata
- Authors
- LeWitt, P. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-12-04
- Volume
- 359
- Issue
- 23
- Pages
- 2468-2476
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1993408885
- Cited by
- 312
- References
- 84
- FWCI
- 11.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.